Fig. 1

The level of PA or OA is associated with the efficacy of Vγ9Vδ2-T cell-based anticancer therapy in patients. a Diagram showing the protocol for collecting serum of HCC patients treated with Vγ9Vδ2-T cells. b Mass spectrometric analysis of FAs in serum of cancer patients before Vγ9Vδ2-T cell therapy (n = 7). c Serum FFA levels of seven cancer patients who received Vγ9Vδ2-T cell treatment are displayed in violin plots. FA levels were measured at baseline and before each Vγ9Vδ2-T cell infusion, corresponding to all timepoints in (a), for responders and non-responders until therapy cessation. Patients with complete response to Vγ9Vδ2-T cell therapy are represented by blue violin plots, and patients with progressive disease under Vγ9Vδ2-T cell therapy are represented by red violin plots. d Correlation between average serum level of PA, OA, or ratio of PA/OA and survival time of patients. The data are shown as the mean ± SEM